Dr Josefin Ahnström is a Lecturer in Haematology in the Centre for Haematology.
She obtained an MSc in Pharmaceutical sciences from Uppsala University, Sweden. In 2009 she was awarded her PhD from Lund University after performing structural and functional studies on apolipoprotein M in Professor Björn Dahlbäck's lab. Following on from her PhD, Josefin joined the Thrombosis and Haemostasis group, led by Professor David Lane and Professor James Crawley, at the Centre for Haematology at Imperial College as a post-doc in September 2009. During her post-doc, she developed an interest in the molecular mechanisms involved in the regulation of coagulation. In 2013 she was awarded a BHF-funded Intermediate Basic Science Research Fellowship and was appointed as a Lecturer in October 2019.
Throughout her career at Imperial College, Josefin’s research interests have continued to focus around structural and functional studies of various coagulation proteins. Her main focus is related regulation of coagulation through the three anticoagulant pathways, with a particular focus on the tissue factor pathway inhibitor (TFPI) and activated protein C (APC) pathways. Through this research, Josefin is investigating how the various components of these pathways are associated with thrombotic risk and their suitability as therapeutic targets when preventing bleeding or thrombosis.
Further details on Josefin’s research are available from the Haemostasis Lab Homepage
Josefin also teaches in several courses at Imperial College London and is the Module 1 lead in the BSc in Haematology. She is also involved in outreach programmes, including being a registered STEM ambassador and acting as a scientific advisor in the “Invisible warrior – sickle cell disease” project. In these programmes, Josefin visits schools where she talks about her career as a scientist and is passionate about encouraging girls to pursue a career in STEM.
Josefin is also since 2017 a committee member of the British Society for Haemostasis and Thrombosis.
et al., 2021, Identification of novel ADAMTS1, ADAMTS4 and ADAMTS5 cleavage sites in versican using a label-free quantitative proteomics approach., Journal of Proteomics, Vol:249, ISSN:0165-022X, Pages:1-8
Ahnstrom J, 2021, FV/FVa revealed, Blood, Vol:137, ISSN:0006-4971, Pages:3011-3013
Ahnström J, Gilbert GE, 2021, Factor V mutation illuminates the dominant anticoagulant role and importance of an unidentified platelet modifier, Journal of Thrombosis and Haemostasis, Vol:19, ISSN:1538-7836, Pages:1168-1170
et al., 2021, Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI, Proceedings of the National Academy of Sciences of the United States of America, Vol:118, ISSN:0027-8424, Pages:1-9
et al., 2021, Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide, Scientific Reports, Vol:11, ISSN:2045-2322